Regulation (EU) 2020/10432020/0128(COD)COM(2020)261

Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease

Stage: In force, reached 17 Jul 2020
In force: In force since 18 Jul 2020 · CELEX 32020R1043
Procedure: Ordinary legislative procedure
Lead DG: DG SANTE
Last activity: 14 Sept 2020

16 entries · record as of 14 Sept 2026

Where it stands

Latest: Discussions within the Council or its preparatory bodies, 14 Sept 2020.

Show the earlier record: 3 dates, 17 Jun 2020 to 1 Jul 2020

17 Jun 2020
- Adoption by Commission
19 Jun 2020
- Discussions within the Council or its preparatory bodies
- Plenary sitting
- Referred to committee
1 Jul 2020
- Discussions within the Council or its preparatory bodies

3 Jul 2020
- Discussions within the Council or its preparatory bodies
8 Jul 2020
- Plenary vote
- Plenary sitting
10 Jul 2020
- Plenary adopted first-reading position
- Plenary vote
- Plenary sitting
13 Jul 2020
- Discussions within the Council or its preparatory bodies
14 Jul 2020
- Approval of the EP's first reading position by the Council (adoption of the legislative act)
15 Jul 2020
- Signed
17 Jul 2020
- Published in the Official Journal
14 Sept 2020
- Discussions within the Council or its preparatory bodies

4 documents

Documents

Newest first. Each opens at its source.

Proposal · COM(2020)0261Parliament
Text adopted · OJ L 231 17.07.2020, p. 0012Commission
Text adopted · Regulation 2020/1043Commission
Text adopted · T9-0203/2020Parliament

Summary

Generated

This temporary regulation expedites clinical trials and market supply for COVID-19 treatments and vaccines that are genetically modified organisms (GMOs). It primarily affects pharmaceutical developers, clinical trial sponsors, and national competent authorities for medicines and GMOs. Adopted under an urgent procedure, it entered into force in July 2020.

What the workspace adds on this file

Everything above is the public record. Subscribers see this page with their own layer on top.

Why it matters to you

What this file means for your organization, assessed against your own priorities.

What moved

When this file moves, it reaches your own briefing, with a link to its source.

Your contacts on it

Your team's contacts logged against this file: who you met, what was said and the next step.

A first draft

A statement, a member update or a meeting brief on this file, in your organization's voice, with its sources.

Sources: EP Legislative Observatory · EUR-Lex. Record as of 14 Sept 2026. Something wrong on this page? Report an error.

Request access

See this file with your own layer on top: why it matters to you, your contacts on it and a first draft. We’ll schedule a 20-minute walkthrough.

EU-hosted · GDPR-compliant · Trust Center →

By submitting, you agree to our privacy policy.